Targeted Combined Approaches for the Treatment of Type 2 Diabetes: The Role of the Kidney

Diabetology
Curriculum:
Targeted Combined Approaches for the Treatment of Type 2 Diabetes: The Role of the Kidney
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
October 27, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

This educational initiative has been designed for family medicine, internal medicine, and osteopathic physicians involved in the management of patients with type 2 diabetes mellitus (T2DM).

Relevant Terms:

Diabetes, T2DM, Kidney, SGLT2

Jennifer B. Green, MD

Jennifer B. Green, MD
Associate Professor of Medicine
Department of Medicine
Division of Endocrinology, Metabolism, and Nutrition
Duke University
Durham, North Carolina

Dr. Green is Associate Professor of Medicine in the Division of Endocrinology at Duke University Medical Center in Durham, North Carolina. She is also Chief of the Endocrine Section at the Durham VA Medical Center.
 
Dr. Green received her medical degree from the University of Virginia School of Medicine in Charlottesville, Virginia. She completed her internship and residency in internal medicine at University of North Carolina in Chapel Hill. She completed a fellowship in endocrinology at Duke University Medical Center.
 
Dr. Green has written extensively on diabetes, including publications in Diabetes Care, Journal of Diabetes and It’s Complications, and Journal of the American Geriatrics Society. She is currently a faculty member of the Endocrine Self-Assessment Committee. 
1. Implement current evidence-based guidelines for the detection and diagnosis of prediabetes and diabetes 
2. Describe the role of the kidney and sodium-glucose co-transporter 2 (SGLT2) inhibition-based therapeutic strategies 
3. Apply evidence-based and individualized management strategies to ensure appropriate and effective management of T2DM

Estimated Time to Complete Activity: 1.0 hours

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this enduring activity for 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
 
The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
 
Jennifer B. Green, MD
Consultant: Merck
Contracted Research: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck 
 
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Media
Internet
 
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. During the period of October 27, 2015 through October 27, 2016, participants must:
 
  • Read the learning objectives and faculty disclosure
  • Study the educational activity
  • Complete the posttest and evaluation form following the activity
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Inc., and AstraZeneca, do not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and AstraZeneca. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support
This educational activity is supported by an educational grant from AstraZeneca. 

Integrity Continuing Education
For questions about the accreditation of this activity, please contact Integrity Continuing Education at 888-255-1009 or information@integrityce.com.

Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above